DSBM OKs EntreMed's MKC-1 breast cancer trial
USA-based pharmaceutical company EntreMed says that an independent Data Safety Monitoring Board's review of a Phase II trial of its anticancer agent MKC-1 has concluded that the risks associated with the drug are "appropriate for the population under study."
The trial is examining MKC-1 as a therapy for women with advanced or metastatic breast cancer who have not responded to conventional therapy. EntreMed added that the DSMB felt the program did not require modification, and that it should continue as planned. The firm also said that the compound is being examined in patients with non-small cell lung cancer and hematological malignancies.
EntreMed added that it has purchased the remaining bulk quantities of the active pharmaceutical ingredient used in the manufacture of the drug from Swiss pharmaceutical firm Roche, from which it obtained a worldwide license to develop and commercialize the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze